北京招聘

1、Proactively assess the relevant market dynamics of therapeutic antibodies, including biosimilars, especially in the areas of treatment for cancers and autoimmune diseases; 
2、Develop and implement plans in business partnerships, including R&D collaborations and commercial partnerships. Develop and grow a productive network of external business relations and maintain strong working relationships with industry counterparts and relative organizations; 
3、Conduct exploratory primary market research and gain insights regarding the clinical and commercial attractiveness of product development opportunities; Provides support to company decision-making during due diligence for in/out-licensing opportunities, collaborations, and partnering activities; 
4、Present the business case based on the findings from diligence and make recommendations related to key opportunities and strength, weakness and risks to Bio-Thera senior management team.  Develop and negotiate term sheets diligently, and identify solutions when needed to reach agreement on key deal terms;
5、Continuously monitors public and private competitors, keeping abreast of regulatory, commercial, and financial developments that are related to Bio-Thera business activities. This position reports to senior VP of BD.

百奥泰生物制药股份有限公司（股票代码：688177）秉承“创新只为生命”的理念，致力于开发新一代创新药和生物类似药，用于治疗肿瘤、自身免疫性疾病、心血管疾病以及其它危及人类生命或健康的重大疾病。公司已推动五款候选药物进入后期临床试验，其中格乐立（阿达木单抗）已在中国获批用于治疗类风湿关节炎、强直性脊柱炎、银屑病、克罗恩病和葡萄膜炎。此外，公司另有多款主攻肿瘤和自身免疫性疾病的候选药物处于不同的临床开发阶段。公司始终以患者的福祉作为首要核心价值，通过创新研发为患者提供安全、有效、可负担的优质药物，以满足亟待解决的治疗需求。欲了解更多信息，请访问公司官网或关注我们的微信公众号“百奥泰”。
Bio-Thera？Solutions, Ltd.a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI, a biosimilar to？Humira？(adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis,？Crohn's disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.